Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MeiraGTx Holdings plcMGTX · Entity 4734 | 10% owner | August 12, 2024 | August 13, 2024 |
| Translate Bio, Inc.TBIO · Entity 135439 | 10% owner | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MeiraGTx Holdings plc
Report date August 12, 2024 · Filed August 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares ($0.00003881 par value per share)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Sanofi Foreign Participations B.V. | 11,500,000 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,500,000 F1: Sanofi is the beneficial owner of Ordinary Shares of the Issuer through its wholly owned subsidiaries Sanofi Foreign Participations B.V. and Kadmon Corporation, LLC. |
| Ordinary Shares ($0.00003881 par value per share)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary Kadmon Corporation, LLC | 697,737 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 697,737 F1: Sanofi is the beneficial owner of Ordinary Shares of the Issuer through its wholly owned subsidiaries Sanofi Foreign Participations B.V. and Kadmon Corporation, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Sanofi is the beneficial owner of Ordinary Shares of the Issuer through its wholly owned subsidiaries Sanofi Foreign Participations B.V. and Kadmon Corporation, LLC.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 55,152,046 |
Reported balance
After 2021-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-09-14 · Purchase · Acquired 51,467,612 · Balance 55,152,046 F1: Shares of Common Stock, par value $0.001 per share (the "Shares"), of Translate Bio, Inc. ("Translate Bio") acquired by Sanofi and its wholly-owned subsidiaries pursuant to the tender offer effected pursuant to the Agreement and Plan of Merger, dated as of August 2, 2021 (the "Merger Agreement"), by and among Sanofi, Vector Merger Sub, Inc., an indirect, wholly owned subsidiary of Sanofi ("Merger Sub"), and Translate Bio (such tender offer, the "Offer"). Prior to the Offer, Sanofi beneficially owned 3,684,434 Shares (approximately 4.87%). |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 75,668,031 |
Reported balance
After 2021-09-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-09-14 · Purchase · Acquired 20,515,985 · Balance 75,668,031 F2: Reflects all of the outstanding Shares not tendered in the Offer and not owned by Sanofi or its wholly-owned subsidiaries prior to the Offer, which may be deemed to have been acquired pursuant to the consummation of the Merger (as defined below). Pursuant to the Merger, Sanofi now beneficially owns all outstanding Shares. F3: Following the consummation of the Offer, Merger Sub was merged with and into Translate Bio, and Translate Bio survived the Merger as an indirect, wholly-owned subsidiary of Sanofi pursuant to a "back-end merger" under Delaware law (the "Merger"). Prior to the Merger, Sanofi indirectly held 100 shares of Merger Sub, which represented all of the issued and outstanding capital stock of Merger Sub. At the effective time of the Merger, all of the shares of Merger Sub were converted into 71,983,597 shares of Translate Bio stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock, par value $0.001 per share (the "Shares"), of Translate Bio, Inc. ("Translate Bio") acquired by Sanofi and its wholly-owned subsidiaries pursuant to the tender offer effected pursuant to the Agreement and Plan of Merger, dated as of August 2, 2021 (the "Merger Agreement"), by and among Sanofi, Vector Merger Sub, Inc., an indirect, wholly owned subsidiary of Sanofi ("Merger Sub"), and Translate Bio (such tender offer, the "Offer"). Prior to the Offer, Sanofi beneficially owned 3,684,434 Shares (approximately 4.87%).
F2: Reflects all of the outstanding Shares not tendered in the Offer and not owned by Sanofi or its wholly-owned subsidiaries prior to the Offer, which may be deemed to have been acquired pursuant to the consummation of the Merger (as defined below). Pursuant to the Merger, Sanofi now beneficially owns all outstanding Shares.
F3: Following the consummation of the Offer, Merger Sub was merged with and into Translate Bio, and Translate Bio survived the Merger as an indirect, wholly-owned subsidiary of Sanofi pursuant to a "back-end merger" under Delaware law (the "Merger"). Prior to the Merger, Sanofi indirectly held 100 shares of Merger Sub, which represented all of the issued and outstanding capital stock of Merger Sub. At the effective time of the Merger, all of the shares of Merger Sub were converted into 71,983,597 shares of Translate Bio stock.
Past disclosures · reporting ended (8)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALNYLAM PHARMACEUTICALS, INC.
Report date January 17, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Attovia Therapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
Section 16 reporting ended · disclosed 2026-08-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,082,855 |
Last balance in matching sequence
After 2026-08-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-06 · Conversion · Acquired 782,855 · Balance 782,855 F1: The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. Row 2 · 2026-08-06 · Purchase · Acquired 300,000 · Balance 1,082,855 F2: Represents a purchase in the Issuer's IPO. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-06 · Conversion · Disposed 782,855 · Balance 0 F1: The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.
F2: Represents a purchase in the Issuer's IPO.
F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
Fulcrum Therapeutics, Inc.
Report date July 22, 2019 · Filed July 23, 2019
Section 16 reporting ended · disclosed 2019-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (par value $0.001)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 464,285 |
Reported balance
After 2019-07-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-07-22 · Conversion · Acquired 464,285 · Balance 464,285 F1: On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC. |
| Common Stock (par value $0.001)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 558,035 |
Reported balance
After 2019-07-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-07-22 · Purchase · Acquired 93,750 · Balance 558,035 F2: The reporting person acquired additional shares in the Issuer's initial public offering. |
| Series B Preferred Stock (par value $0.001)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 0 |
Reported balance
After 2019-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-22 · Conversion · Disposed 3,250,000 · Balance 0 F1: On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC.
F2: The reporting person acquired additional shares in the Issuer's initial public offering.
Icosavax, Inc.
Report date August 02, 2021 · Filed August 03, 2021
Section 16 reporting ended · disclosed 2021-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (par value, $0.0001)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 3,155,169 |
Last balance in matching sequence
After 2021-08-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-08-02 · Conversion · Acquired 3,088,502 · Balance 3,088,502 F1: On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer. F2: Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc. Row 2 · 2021-08-02 · Purchase · Acquired 66,667 · Balance 3,155,169 F3: The reporting person acquired additional shares in the Issuer's initial public offering. F2: Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc. |
| Series A-1 Preferred Stock (par value, $0.0001)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectThrough its wholly-owned subsidiary, Aventis Inc | 0 |
Reported balance
After 2021-08-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-02 · Conversion · Disposed 12,480,498 · Balance 0 F1: On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer. F2: Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc. |
| Series B-1 Preferred Stock (par value, $0.0001)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectThrough its wholly-owned subsidiary, Aventis Inc | 0 |
Reported balance
After 2021-08-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-02 · Conversion · Disposed 354,393 · Balance 0 F1: On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer. F2: Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
F2: Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc.
F3: The reporting person acquired additional shares in the Issuer's initial public offering.
Inozyme Pharma, Inc.
Report date July 28, 2020 · Filed July 29, 2020
Section 16 reporting ended · disclosed 2020-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (par value $0.0001)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 438,875 |
Reported balance
After 2020-07-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-07-28 · Conversion · Acquired 438,875 · Balance 438,875 F1: On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY. |
| Common Stock (par value $0.0001)SEC Table I · non-derivative | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 520,125 |
Reported balance
After 2020-07-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-28 · Purchase · Acquired 81,250 · Balance 520,125 F2: The reporting person acquired additional shares in the Issuer's initial public offering. |
| Series A Convertible Preferred Stock (par value, $0.0001)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectThrough its wholly-owned subsidiary, Aventis Inc. | 0 |
Reported balance
After 2020-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-28 · Conversion · Disposed 3,279,720 · Balance 0 F1: On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY.
F2: The reporting person acquired additional shares in the Issuer's initial public offering.
Latigo Biotherapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 494,800 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Conversion · Acquired 494,800 · Balance 494,800 F1: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 672,788 |
Reported balance
After 2026-08-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-10 · Conversion · Acquired 177,978 · Balance 672,788 F2: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Disposed 494,800 · Balance 0 F1: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-08-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-10 · Conversion · Disposed 177,978 · Balance 0 F2: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration.
F2: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock.
F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
MyoKardia, Inc.
Report date February 13, 2019 · Filed February 15, 2019
Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (par value $0.0001)SEC Table I · non-derivative | IndirectVia wholly-owned subsidiary, Aventis Inc. | 0 |
Reported balance
After 2019-02-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-02-13 · Sale · Disposed 4,168,899 · Balance 0 F1: On February 13, 2019, the reporting person sold 4,168,899 shares of MYOK at a price of $37.66 (the "Transaction"). As a result of the Transaction, the reporting person no longer owns shares of common stock of MYOK and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of MYOK. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 13, 2019, the reporting person sold 4,168,899 shares of MYOK at a price of $37.66 (the "Transaction"). As a result of the Transaction, the reporting person no longer owns shares of common stock of MYOK and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of MYOK.
REGENERON PHARMACEUTICALS, INC.
Report date June 09, 2020 · Filed June 11, 2020
Section 16 reporting ended · disclosed 2020-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee note | 279,766 |
Reported balance
After 2020-06-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-06-09 · Sale · Disposed 120,234 · Balance 279,766 F1: Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D. F3: Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the "Sanofi Parties") and the Issuer, as amended, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. F2: Directly owned by Aventisub LLC ("Aventisub"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D.
F2: Directly owned by Aventisub LLC ("Aventisub"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person.
F3: Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the "Sanofi Parties") and the Issuer, as amended, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 5,103 | $475.93 | $2,428,680.49 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 7 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,710,075 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F10 · price: Purchase prices range from $475.55 to $476.43 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,633 | $474.86 | $1,250,300.59 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 6 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,704,972 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F9 · price: Purchase prices range from $474.40 to $475.21 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 13,037 | $480.37 | $6,262,624.10 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 5 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,702,339 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F8 · price: Purchase prices range from $479.91 to $480.86 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 23,872 | $479.45 | $11,445,454.27 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,689,302 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F7 · price: Purchase prices range from $478.89 to $479.87 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 12,186 | $478.34 | $5,829,078.05 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,665,430 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F6 · price: Purchase prices range from $477.81 to $478.80 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 9,600 | $477.35 | $4,582,544.64 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,653,244 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F5 · price: Purchase prices range from $476.78 to $477.75 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 1,900 | $475.97 | $904,349.08 |
DisclosureSEC source: 0001140361-17-033310 · form4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,643,644 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $475.51 to $476.50 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | PurchaseCommon stock Par value per share $ 0.0001 | 350,000 | $35.50 | $12,425,000.00 |
DisclosureSEC source: 0000899243-17-020410 · doc4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary Aventis Inc. Disclosed balance after: 4,018,899 Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 4,708 | $484.04 | $2,278,844.78 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 15 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,641,744 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F18 · price: Purchase prices range from $483.57 to $484.50 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 18,311 | $483.04 | $8,844,950.93 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 14 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,637,036 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F17 · price: Purchase prices range from $482.57 to $483.50 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 23,490 | $482.08 | $11,324,033.36 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 13 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,618,725 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F16 · price: Purchase prices range from $481.57 to $482.56 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 15,197 | $481.13 | $7,311,720.45 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 12 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,595,235 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F15 · price: Purchase prices range from $480.54 to $481.53 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 12,710 | $480.17 | $6,102,958.16 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 11 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,580,038 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F14 · price: Purchase prices range from $479.54 to $480.51 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 6,507 | $478.94 | $3,116,482.75 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 10 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,567,328 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F13 · price: Purchase prices range from $478.53 to $479.48 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 6,312 | $476.15 | $3,005,441.13 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 9 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,560,821 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F12 · price: Purchase prices range from $475.70 to $476.47 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 12,020 | $475.16 | $5,711,414.79 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 8 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,554,509 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F11 · price: Purchase prices range from $474.50 to $475.49 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 7,068 | $473.88 | $3,349,414.23 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 7 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,542,489 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F10 · price: Purchase prices range from $473.45 to $474.10 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 5,806 | $473.07 | $2,746,650.81 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 6 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,535,421 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F9 · price: Purchase prices range from $472.45 to $473.33 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 7,443 | $471.82 | $3,511,789.75 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 5 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,529,615 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F8 · price: Purchase prices range from $471.43 to $472.25 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 13,544 | $470.72 | $6,375,496.69 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,522,172 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F7 · price: Purchase prices range from $470.31 to $470.99 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,132 | $469.81 | $1,001,634.28 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,508,628 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F6 · price: Purchase prices range from $469.19 to $470.04 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 400 | $468.10 | $187,240.00 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,506,496 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F5 · price: Purchase prices range from $468.01 to $468.29 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 402 | $466.38 | $187,485.89 |
DisclosureSEC source: 0001140361-17-023988 · form4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,506,096 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $465.88 to $466.56 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 23:41 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | PurchaseCommon Stock | 297,501 | $71.87 | $21,381,396.87 |
DisclosureSEC source: 0000899243-17-015022 · doc4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly-owned subsidiary, Genzyme Corp. Disclosed balance after: 10,554,134 F1 · shares: Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,110 | $379.56 | $800,879.20 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 18 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,505,694 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F21 · price: Purchase prices range from $379.38 to $379.80 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 9,520 | $378.76 | $3,605,828.52 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 17 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,503,584 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F20 · price: Purchase prices range from $378.37 to $379.36 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 5,313 | $377.84 | $2,007,446.92 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 16 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,494,064 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F19 · price: Purchase prices range from $377.36 to $378.35 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 3,851 | $376.75 | $1,450,859.63 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 15 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,488,751 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F18 · price: Purchase prices range from $376.36 to $377.34 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 3,016 | $375.88 | $1,133,650.76 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 14 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,484,900 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F17 · price: Purchase prices range from $375.36 to $376.34 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 3,830 | $374.59 | $1,434,688.13 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 13 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,481,884 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F16 · price: Purchase prices range from $374.31 to $375.24 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,784 | $373.90 | $1,040,942.61 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 12 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,478,054 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F15 · price: Purchase prices range from $373.30 to $374.28 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,675 | $372.87 | $997,438.22 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 11 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,475,270 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F14 · price: Purchase prices range from $372.29 to $373.27 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 1,259 | $371.53 | $467,762.06 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 10 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,472,595 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F13 · price: Purchase prices range from $371.05 to $372.02 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 900 | $370.18 | $333,161.01 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 9 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,471,336 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F12 · price: Purchase prices range from $369.87 to $370.59 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,517 | $369.30 | $929,528.10 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 8 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,470,436 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F11 · price: Purchase prices range from $368.84 to $369.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 2,336 | $368.35 | $860,459.06 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 7 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,467,919 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F10 · price: Purchase prices range from $367.84 to $368.78 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 1,986 | $367.29 | $729,440.12 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 6 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,465,583 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F9 · price: Purchase prices range from $366.83 to $367.81 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 3,979 | $366.05 | $1,456,524.09 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 5 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,463,597 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F8 · price: Purchase prices range from $365.80 to $366.73 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 19,858 | $365.20 | $7,252,177.34 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,459,618 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F7 · price: Purchase prices range from $364.80 to $365.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 13,226 | $364.32 | $4,818,528.06 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,439,760 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F6 · price: Purchase prices range from $363.80 to $364.77 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 6,546 | $363.35 | $2,378,511.36 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,426,534 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F5 · price: Purchase prices range from $362.80 to $363.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | PurchaseCommon Stock | 1,592 | $362.47 | $577,046.51 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,419,988 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $361.76 to $362.71 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 13:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | PurchaseCommon stock Par value per share $ 0.0001 | 450,000 | $15.00 | $6,750,000.00 |
DisclosureSEC source: 0000899243-16-031096 · doc4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary Aventis Inc. Disclosed balance after: 3,668,899 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.